Inceptor Bio is developing next-generation cell and gene therapy platforms to deliver cures for underserved and difficult-to-treat cancers. The company has a proprietary CAR-M platform, which uses monocytes and macrophages engineered with a Chimeric Antigen Receptor (CAR) to identify and attack cancer cells. Inceptor Bio's CAR-M platform has several advantages over other cell therapy approaches, including: increased infiltration into tumors, enhanced phagocytosis, overcoming the CD47/SIRP⍺ ('Don't Eat Me') signal. Inceptor Bio is currently developing CAR-M therapies for a variety of solid tumors, including pancreatic cancer, glioblastoma, and non-small cell lung cancer.

Inceptor Bio

Short description:

Drug notes:

Long description:

Jobs: